Zepbound Side Effects: What to Expect
Every reaction the tirzepatide trial program recorded, alongside the boxed warning and the Section 5 risks its FDA label carries.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Reaction rates and warnings here are read from the FDA label for Zepbound. Most of what a GLP-1 produces is gut-related and peaks in the days after a dose goes up, so the Zepbound dosing page shows where each step falls. The Zepbound drug guide covers the rest of the drug.
Most Common Zepbound Side Effects
Every reaction the Zepbound FDA label records, showing how often it appeared among tirzepatide-treated patients and how often it appeared on placebo. The figures are taken from the label's Section 6, DailyMed SetID487cd7e7-434c-4925-99fa-aa80b1cc776b.
| Adverse reaction | Incidence (Zepbound vs placebo) |
|---|---|
| Nausea | 25–29% (placebo 8%) |
| Diarrhea | 19–23% (placebo 8%) |
| Vomiting | 8–13% (placebo 2%) |
| Constipation | 11–17% (placebo 5%) |
| Abdominal pain | 9–10% (placebo 5%) |
| Dyspepsia | 9–10% (placebo 4%) |
| Injection site reactions | 6–8% (placebo 2%) |
| Fatigue | 5–7% (placebo 3%) |
| Hypersensitivity reactions | 5% (placebo 3%) |
| Eructation (burping) | 4–5% (placebo 1%) |
| Hair loss (alopecia) | 4–5% (placebo 1%) |
| Gastroesophageal reflux disease (GERD) | 4–5% (placebo 2%) |
Source: Zepbound FDA prescribing information via DailyMed (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b), Section 6 Adverse Reactions, read on 2026-05-31. Treat this as a summary — the full label is the document, and a prescriber is the person to discuss it with.
Boxed Warning — Thyroid C-Cell Tumors
“In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”
Quoted word for word from the Zepbound FDA label (DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b). Nothing the FDA issues carries more weight than a boxed warning. Your own history and your family's both need to be on the table before you start Zepbound, and that means talking to a licensed prescriber.
Serious Warnings & Precautions
Past the everyday reactions above, Section 5 of the Zepbound label sets out these serious risks. They arrive far less often, and some of them need care the same day — which is why the symptoms are worth knowing and when to seek care.
- Risk of thyroid C-cell tumors
- Severe gastrointestinal adverse reactions
- Acute kidney injury due to volume depletion
- Acute gallbladder disease
- Acute pancreatitis
- Hypersensitivity reactions
- Hypoglycemia
- Diabetic retinopathy complications in patients with type 2 diabetes mellitus
- Pulmonary aspiration during general anesthesia or deep sedation
Compare every Zepbound provider
Every warning above is something a prescriber screens for before writing anything. Current price, verification status, product form and the states each seller ships to are all on one screen.
Related deep-dives
What to do about each symptom, and the evidence underneath it, is covered here:
- How long GLP-1 side effects last →
- Hair loss and muscle loss on a GLP-1 →
- Pancreatitis and gallbladder risk →
- What the thyroid cancer warning rests on →
- Eye risk: NAION and retinopathy →
- Drinking on a GLP-1 →
- What happens when you stop →
- Where to inject, and why the site matters →
- Tirzepatide side effects over the long run →
- Side effects reported on compounded tirzepatide →